Basic Information
Izba
Regulatory Information
EMEA/H/C/002738
February 20, 2014
8
November 29, 2021
Company Information
Ireland
Elm Park Merrion Road Dublin 4
NOVARTIS EUROPHARM LIMITED
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with ocular hypertension or paediatric glaucoma.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Izba. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Izba. For practical information about using Izba, patients should read the package leaflet or contact their doctor or pharmacist.